NewAmsterdam Pharma(NAMSW)
NARRDEN, NetherlandsPharmaceutical
Focus: NewAmsterdam Pharma is a public, small-molecule focused biotech company headquartered in the Netherlands, advancing programs across metabolic diseases, cardiovascular, and neurology. The company recently achieved its first EU drug approval for Obicetrapib in 2026.
Profile data last refreshed 1h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Total Funding
$196M
Open Jobs
10-1 this month
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Should You Work at NewAmsterdam Pharma?
AI assessmentA high-risk, high-reward opportunity for scientists and regulators willing to bet on commercial execution of an EU-approved asset, but not suitable for those seeking stability or established revenue scale.
Why Work Here
- Recent EU approval of Obicetrapib validates lead program and signals transition from development-stage to commercial biotech with pipeline depth across 5 therapeutic areas.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$14M
Pipeline & Clinical Trials
Corrie Lipids Digital Health Program
Cardiovascular RiskClinical Trials (1)
NCT07478887Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
N/AHelp build intelligence for NewAmsterdam Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.